- Cheryl Renz
- Head of Benefit-Risk Management, Pharmacovigilance and Patient Safety
- AbbVie, United States
Cheryl Renz, MD is Head of the Benefit-Risk Management group for the Pharmacovigilance and Patient Safety organization at AbbVie(formally Abbott). Her group leads company-wide benefit-risk evaluations as well as the development and implementation of risk management strategies. She has led process improvement initiatives for preparation of risk management plans and compliance oversight of global risk minimization / REMS programs. Cheryl has nearly 20 years of experience in the pharmaceutical industry. Prior to joining the pharmacovigilance organization she served as Project Director in Global Research and Development (for Abbott) and led clinical development programs across multiple therapeutic areas, including virology (Kaletra), immunology (Humira), metabolics (Sibutramine), respiratory, neuroscience (Depakote), and pain. Cheryl received a Doctor of Medicine degree from the University of Chicago’s Pritzker School of Medicine, and Master's and Bachelor's degrees in Biochemistry from the University of Rochester. She completed residency and fellowship training in Internal Medicine, Pulmonary and Critical Care Medicine and Clinical Pharmacology at the University of Chicago Hospitals.